ISCO reports positive results from pre-clinical in vivo Parkinson's disease study.
Our proprietary technology is based on a homogeneous population of neuronal cells (NCs) derived from homozygous hpSCs through a scalable and efficient method, developed by ISCO's R&D team. These parthenogenetically-derived NCs are cryopreservable and can become neurons once they are implanted into the brain. As such, they hold significant therapeutic potential not only because they can differentiate into dopamine-producing neurons, but also because these cells deliver trophic factors that may be able to provide a level of protection to existing neurons affected by the disease.
Of course this is with primates but seems too have real potential.
02-06-2013, 09:21 PM
Reply With Quote
Similar Threads
Promising stem cell treatment
Linear Mode
